The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells
Jennifer A. Mertz(Constellation Pharmaceuticals (United States)), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Patrick Trojer(Morpho (United States)), Gozde Colak(Morpho (United States)), Jike Cui(Morpho (United States)), Patricia J. Keller(Constellation Pharmaceuticals (United States)), Adam J. Mead(National Institute for Health and Care Research), Rosana Meyer(Boston University), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Adrian M. Senderowicz, James Shao(Sarepta Therapeutics (United States)), Katarina Luptakova(Tesaro (United States)), Vikas Gupta(Indian Institute of Technology Kanpur), John Mascarenhas(Tisch Hospital), Srđan Verstovšek(Unknown), Claire Harrison(National Health Service), Jeffrey S. Humphrey, Oksana Zavidij(Constellation Pharmaceuticals (United States)), Jean‐Jacques Kiladjian(Délégation Paris 5), Jing Wang(Constellation Pharmaceuticals (United States)), Moshe Talpaz(University of Michigan)
Cited by 3
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k